ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

EULAR Releases 2016 Gout Treatment Guidelines

EULAR Releases 2016 Gout Treatment Guidelines

The European League Against Rheumatism (EULAR) issued new gout treatment guidelines this week, the first since 2006.

Much has changed in the understanding of gout since the guidelines were last issued.

There has been a dramatic increase in the prevalence of gout in developed countries and there is now mounting evidence for a clear association between gout and cardiovascular events, kidney failure and mortality. This “has heightened the realization that gout should never be neglected and should be treated properly,” wrote Pascal Richette, M.D., Ph.D., and colleagues in the July 25 issue of the Annals of the Rheumatic Diseases.

The 2016 recommendations are based on a systematic literature review of 984 references of studies that focused on treating flares and long-term management of gout. The guidelines were written, in part, with the primary care physician in mind since they often treat gout patients first.  ©ThamKC/Shutterstock.com©ThamKC/Shutterstock.com

While colchicine, non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids have traditionally been used to manage gout flares, now patients have new treatment options, such as allopurinol (Zyloprim), febuxostat (Uloric), pegloticase (Krystexxa) and interleukin-1 inhibitors (anakinra, canakinumab, rilonacept) for frequent and poorly controlled flaresBecause of the high cost of IL-1 blockers and an increased likelihood of infection, the EULAR task force recommends they be prescribed only for patients who have contraindications to colchicine, NSAIDs and corticosteroids.

Citing multiple studies, the authors say that urate-lowering therapy (ULT), specifically allopurinol, should be considered at first presentation of a flare. If this fails, then febuxostat, or a combination of a xanthine oxidase inhibitor with a uricosuric, should be considered. For refractory gout, EULAR recommends pegloticase.

They recommend serum uric acid (SUA) target levels of less than 6 mg/dL (360 mmol/L) for mild to moderate gout and for patients with severe gout, less than 5 mg/dL (300 mmol/L).

While new pharmacological treatments can be effective in managing gout flares, pharmacological treatments must be applied with patient education, the authors stressed repeatedly in the article. Fostering an environment in which patients take an active role in controlling flares — through medication adherence and lifestyle changes — is essential. “The task force is convinced that patients must play a key role and be fully involved in the management of their disease,” the authors wrote.

 

How the EULAR and ACR Gout Recommendations Differ

(Continued on next page.)

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.